First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations...
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutationsZKN-013 is a phase I...
VANCOUVER, Wash. and BARCELONA, Spain, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, and Almirall S.A. (BME: ALM), a global...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | -0.01 | -10.5263157895 | 0.095 | 0.1 | 0.075 | 12500 | 0.0778 | CS |
12 | -0.01 | -10.5263157895 | 0.095 | 0.1 | 0.075 | 15438 | 0.08987854 | CS |
26 | 0.005 | 6.25 | 0.08 | 0.14 | 0.07 | 21986 | 0.09585042 | CS |
52 | -0.06 | -41.3793103448 | 0.145 | 0.2 | 0.07 | 31640 | 0.10188493 | CS |
156 | -0.915 | -91.5 | 1 | 1.04 | 0.07 | 19431 | 0.20363471 | CS |
260 | 0.075 | 750 | 0.01 | 1.15 | 0.005 | 82093 | 0.05598769 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.